natgillin/translations-raw huggingface dataset:
In the all-randomised population, capecitabine was shown to be superior to 5FU/LV for disease-free survival (hazard ratio 0.849; 95% CI 0.739 - 0.976; p = 0.0212), as well as for overall survival (hazard ratio 0.828; 95% CI
U cjelokupnoj randomiziranoj populaciji kapecitabina se pokazala superiornijom u odnosu na 5-FU/LV u preživljenju bez znakova bolesti (omjer hazarda 0,849; 95% CI: 0,739 – 0,976; p = 0,0212) kao i u sveukupnom preživljenju (omjer hazarda 0,828; 95% CI: 0,705
In the all-randomised population, capecitabine was shown to be superior to 5FU/LV for disease-free survival (hazard ratio 0.849; 95% CI 0.739 - 0.976; p = 0.0212), as well as for overall survival (hazard ratio 0.828; 95% CI 0.705 - 0.971; p = 0.0203).
U cjelokupnoj randomiziranoj populaciji kapecitabin se pokazao superiornijim u odnosu na 5-FU/LV u preživljenju bez znakova bolesti (omjer hazarda 0,849; 95% CI: 0,739 – 0,976; p = 0,0212) kao i u sveukupnom preživljenju (omjer hazarda 0,828; 95% CI: 0,705 – 0,971; p = 0,0203).
In the all-randomised population, tests for difference of capecitabine vs 5-FU/LV in disease-free and overall survival showed hazard ratios of 0.88 (95%
U cjelokupnoj randomiziranoj populaciji testovi za utvrđivanje razlike između kapecitabina i 5-FU/LV u preživljenju bez znakova bolesti i ukupnom preživljenju pokazali su omjere rizika od 0,88 (95% CI 0,77 – 1,01; p
In the alogliptin group, 12.7% (344 subjects) experienced an event within the secondary MACE composite endpoint, compared with 13.4% (359 subjects) in the placebo group [Hazard Ratio = 0.95; 1-sided 99% Confidence Interval: 0-1.14].
U skupini na alogliptinu, 12,7% (344 ispitanika) imalo je događaj unutar sekundarnog MACE kompozitnog ishoda, u usporedbi s 13,4% (359 ispitanika) u skupini na placebu [omjer hazarda = 0,95; 1-stran 99% Interval pouzdanosti: 0-1,14].
In the alternating treatment study, the treatment schedule combining Ferriprox for five days with deferoxamine for two days reduced blood ferritin levels to the same extent as deferoxamine taken on its own.
U ispitivanju naizmjeničnog liječenja, rasporedom liječenja u kojem se lijek Ferriprox davao pet dana, a deferoksamin dva dana, smanjena je razina feritina u krvi u istoj mjeri kao i kod monoterapije deferoksaminom.
In the AMPLIFY study a total of 5,395 patients were randomised to treatment with apixaban 10 mg twice daily orally for 7 days followed by apixaban 5 mg twice daily orally for 6 months, or enoxaparin 1 mg/kg twice daily subcutaneously for at least 5 days (until INR 2) and warfarin (target INR range 2.0-3.0) orally for 6 months.
U ispitivanju AMPLIFY randomizirano je ukupno 5395 bolesnika u skupine koje su liječene apiksabanom u dozi od 10 mg dvaput na dan peroralno tijekom 7 dana, nakon čega je slijedio apiksaban 5 mg dvaput na dan peroralno tijekom 6 mjeseci, ili enoksaparin 1 mg/kg dvaput na dan potkožno barem 5 dana (do INR 2) i varfarin (ciljni raspon INR 2,0-3,0) peroralno tijekom 6 mjeseci.
In the anti-TNFα-IR patients subgroup, only the 300 mg dose showed significantly higher response rate for ACR 20 compared to placebo (p<0.05) and demonstrated clinical meaningful benefit over 150 mg on multiple secondary endpoints.
U podskupini bolesnika s neodgovarajućim odgovorom na anti-TNFα, samo je doza od 300 mg pokazala značajno višu stopu odgovora za ACR 20 u usporedbi s placebo (p<0,05) i pokazala klinički značajnu korist u odnosu na 150 mg s obzirom na više sekundarnih ishoda.
In the apixaban vs warfarin study the incidence of ISTH major gastrointestinal bleeds (including upper GI, lower GI, and rectal bleeding) with apixaban was 0.76%/year.
U ispitivanju apiksabana u odnosu na varfarin incidencija značajnog gastrointestinalnog krvarenja prema ISTH (uključujući krvarenje u gornjem i donjem dijelu GI trakta i rektalno krvarenje) pri primjeni apiksabana iznosila je 0,76% na godinu.
In the arcuate nucleus of the hypothalamus, bupropion stimulates pro-opiomelanocortin (POMC) neurons that release alpha-melanocyte stimulating hormone (α-MSH), which in turn binds to and stimulates melanocortin 4 receptors (MC4-R).
U arkuatnoj jezgri hipotalamusa, bupropion stimulira neurone pro-opiomelanokortina (engl. pro opiomelanocortin, POMC) koji otpuštaju alfa-hormon koji stimulira melanocite (engl. alpha melanocyte stimulating hormone, α-MSH), koji se zatim veže na i potiče melanokortin 4 receptore (engl. melanocortin 4 receptors, MC4-R).
In the ARIES-E open label long term extension study, the 2 year risk of developing serum aminotransferase elevations >3xULN in patients treated with ambrisentan was 3.9%.
U otvorenom dugoročnom produženom ispitivanju ARIES E, dvogodišnji rizik od razvoja povećanih serumskih razina aminotransferaze >3xGGN u bolesnika liječenih ambrisentanom bio je 3,9%.
In the arteries supplying the lungs (pulmonary embolism)
U arterijama koje opskrbljuju pluća (plućna embolija)
In the AS001 clinical trial, Cimzia-treated patients reported significant improvements in physical function as assessed by the BASFI and in pain as assessed by the Total and Nocturnal Back Pain NRS scales as compared to placebo.
U AS001 kliničkom istraživanju, u bolesnika liječenih Cimzijom u usporedbi s placebom zabilježena su značajna poboljšanja fizikalne funkcije ocjenjujući prema BASFI i u boli ocjenjujući prema ljestvicama Ukupne i noćne boli u leđima (NRS).
In the AVERROES study a total of 5,598 patients considered to be unsuitable for VKA by the investigators were randomised to treatment with apixaban 5 mg twice daily (or 2.5 mg twice daily in selected patients [6.4%], see section 4.2) or ASA.
U ispitivanju AVERROES randomizirano je ukupno 5598 bolesnika, koje su ispitivači ocijenili prikladnima za terapiju antagonistom vitamina K, u skupine koje su liječene apiksabanom u dozi od 5 mg dvaput na dan (ili 2,5 mg dvaput na dan u odabranih bolesnika [6,4%], vidjeti dio 4.2) ili ASK-om.
In the BCIRG 006 study Herceptin was administered either in combination with docetaxel, following AC chemotherapy (AC→DH) or in combination with docetaxel and carboplatin (DCarbH).
U sklopu ispitivanja BCIRG 006 Herceptin je primjenjivan u kombinaciji s docetakselom nakon AC kemoterapije (AC→DH) ili u kombinaciji s docetakselom i karboplatinom (DCarbH).
In the body, 5-FU takes the place of pyrimidine and interferes with the enzymes involved in making new DNA.
U tijelu 5-FU preuzima ulogu pirimidina i interferira s enzimima uključenima u stvaranju novog DNK-a.
In the body, a hormone called ‘thrombopoietin’ stimulates the production of platelets by attaching to certain receptors in the bone marrow.
Hormon trombopoetin u tijelu potiče stvaranje trombocita vezujući se na određene receptore u leđnoj moždini.
In the body, a hormone called ‘thrombopoietin’ stimulates the production of platelets in the bone marrow.
U tijelu hormon trombopoetin stimulira stvaranje trombocita u leđnoj moždini.
In the body, everolimus first attaches to a protein called FKBP-12 that is found inside cells to make a ‘complex’.
Everolimus se u tijelu prvo veže na protein FKBP-12 koji se nalazi unutar stanica kako bi se stvorio „kompleks”.
In the body, everolimus first attaches to a protein called FKBP-12 that is found inside cells to make a ‘complex’.
Everolimus se u tijelu prvo veže na protein naziva FKBP-12 koji se nalazi unutar stanica kako bi se stvorio „kompleks”.
In the body, factor VII is involved in blood clotting.
U tijelu faktor VII sudjeluje u zgrušavanju krvi.
In the body, it is converted into mycophenolic acid, which blocks an enzyme called ‘inosine monophosphate dehydrogenase’.
U tijelu se pretvara u mikofenolnu kiselinu, koja blokira enzim inozin monofosfat dehidrogenazu.
In the body, pemetrexed is converted into an active form that blocks the activity of the enzymes that are involved in producing ‘nucleotides’ (the building blocks of DNA and RNA, the genetic material of cells).
Pemetreksed se u tijelu pretvara u djelatni oblik koji blokira djelovanje enzima uključenih u proizvodnju „nukleotida” (stanica koje grade DNK i RNK, genetski materijal stanica).
In the body, pemetrexed is converted into an active form that blocks the activity of the enzymes that are involved in producing ‘nucleotides’ (the building blocks of DNA and RNA, the genetic material of cells).
Pemetreksed se u tijelu pretvara u djelatni oblik koji onemogućuje djelovanje enzima koji su uključeni u proizvodnju „nukleotida” (temeljnih sastavnica DNK-a i RNK-a, odnosno genetskog materijala stanice).
In the body, pemetrexed is converted into an active form that blocks the activity of the enzymes that are involved in producing ‘nucleotides’ (the building blocks of DNA and RNA, the genetic material of cells).
U tijelu pemetreksed se konvertira u djelatni oblik koji blokira djelovanje enzima koji su uključeni u proizvodnju „nukleotida” (stanica koje grade DNK i RNK, genetski materijal stanica).
In the body, pemetrexed is converted into an active form that blocks the activity of the enzymes that are involved in producing ‘nucleotides’ (the building blocks of DNA and RNA, the genetic material of cells).
U tijelu pemetreksed se pretvara u djelatni oblik koji blokira djelovanje enzima, koji sudjeluju u proizvodnji „nukleotida” (temeljni elementi koji formiraju DNK i RNK, genetski materijal stanica).
In the body, pemetrexed is converted into an active form that blocks the activity of the enzymes that are involved in producing ‘nucleotides’ (the building blocks of DNA and RNA, the genetic material of cells).
U tijelu se pemetreksed konvertira u djelatni oblik koji blokira djelovanje enzima koji su uključeni u proizvodnju „nukleotida” (stanica koje grade DNK i RNK, genetski materijal stanica).
In the body, radium is handled like the calcium naturally found in the bones.
U tijelu radij oponaša kalcij koji se prirodno nalazi u kostima.
In the body, this analogue takes the place of guanine and interferes with the enzymes involved in making new DNA, DNA polymerases.
U tijelu, ovaj analog preuzima ulogu guaninai interferira s enzimima uključenima u izradu nove DNK, DNK polimeraze.
In the body, trifluridine is converted into an active form that is incorporated directly into DNA, the genetic material of cells.
Trifluridin se u tijelu pretvara u djelatni oblik koji se izravno ugrađuje u DNK, genetički materijal stanica.
In the body, waste nitrogen is turned into ammonia, which is harmful when it accumulates.
U tijelu se otpadni dušik pretvara u amonijak koji postaje štetan kada se nakupi.
In the brain it stimulates receptors for GABA, a substance involved in reducing electrical activity in the brain.
Sevofluran u mozgu stimulira receptore GABA-e, tvari koja djeluje na smanjenje električne aktivnosti u mozgu.
In the brain, paliperidone attaches to several different receptors on the surface of nerve cells.
U mozgu, paliperidon se veže na nekoliko različitih receptora na površini živčanih stanica.
In the breast cancer study, patients who took Afinitor lived for an average of 7.8 months without their disease getting worse, compared with 3.2 months for the patients who took placebo.
U ispitivanju bolesnica s rakom dojke, bolesnice koje su uzimale lijek Afinitor živjele su prosječno 7,8 mjeseci bez pogoršanja bolesti u usporedbi s 3,2 mjeseca u slučaju bolesnica koje su uzimale placebo.
In the burn wound study with 61 patients, the mean study wound area was 216 cm2; the total burn injury of these patients was larger and affected 5.8% of the total body surface area.
U ispitivanju rana izazvanih opeklinama u kojem je sudjelovao 61 bolesnik, srednja vrijednost površine ispitivane rane iznosila je 216 cm2; ukupno oštećenje izazvano opeklinama u tih bolesnika bilo je veće te je zahvatilo 5,8 % ukupne površine tijela.
In the C-SURFER study, overall SVR was achieved in 94 % (115/122) of subjects receiving EBR + GZR for 12 weeks.
U ispitivanju C-SURFER, ukupni SVR postiglo je 94% (115/122) ispitanika koji su primali EBR + GZR tijekom 12 tjedana.
In the capsule shell: gelatin, potassium aluminium silicate (E555), titanium dioxide (E171), yellow iron oxide (E172) and indigotine (E132).
U ovojnici kapsule: želatina, kalijev aluminijev silikat (E555), titanijev dioksid (E171), žuti željezov oksid (E172) i indigotin (E132).
In the capsule shell: gelatin, titanium dioxide (E171), indigo carmine (E132).
U ovojnici kapsule: želatina, titanijev dioksid (E171), indigo karmin (E132).
In the capsule: microcrystalline cellulose, lactose monohydrate (see section 2 under ‘Cerdelga contains lactose’), hypromellose and glycerol dibehenate.
U kapsuli: mikrokristalična celuloza, laktoza hidrat (vidjeti dio 2 pod „Cerdelga sadrži laktozu“), hipromeloza i gliceroldibehenat.
In the capsules: microcrystalline cellulose, methacrylic acid - ethyl acrylate copolymer, hypromellose, talc, triethyl citrate, sodium lauryl sulfate.
U kapsulama: mikrokristalična celuloza, metakrilatna kiselina/etilakrilat kopolimer, hipromeloza, talk, trietilcitrat, natrijev laurilsulfat.
In the case both vaccines are used at the same day the size of the local reactions may increase up to 6 cm in individual pigs and may last 5 weeks.
U slučaju primjene oba cjepiva na isti dan, veličina lokalnih reakcija može se povećati do 6 cm u pojedinih svinja i može trajati 5 tjedana.
In the case excess Macugen volume is injected, serious increase in intraocular pressure may occur.
U slučaju da je injiciran veći volumen lijeka Macugen može doći do ozbiljnog povišenja očnog tlaka.
In the case of a group of patients treated with enoxaparin, percutaneous coronary intervention was performed without discontinuation of enoxaparin (without changing the product) administered according to the scheme established in previous studies, i.e.:
U slučaju skupine bolesnika enoksaparinom, perkutana koronarna intervencija je učinjena bez prekidanja enoksaparina (bez mijenjanja lijeka) primjenjivanog prema shemi davanja utvrđenoj u ranijim ispitivanjima, tj.:
In the case of a serious skin reaction, discontinuation of other medicinal products known to be associated with serious skin reactions should be considered.
U slučaju ozbiljne kožne reakcije mora se razmotriti prekid liječenja drugim lijekovima za koje se zna da su povezani s ozbiljnim kožnim reakcijama.
In the case of accidental ingestion, particularly in the case of children, medical advice should be sought immediately and the package leaflet or label shown to the doctor.
Ako se dogodi slučajna ingestija, naročito ako se radi o djetetu, odmah potražite savjet liječnika i pokažite mu uputu ili deklaraciju ovog lijeka.
In the case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
U slučaju da se nehotice proguta, odmah potražiti pomoć liječnika i pokazati mu uputu o VMP ili etiketu.
In the case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
U slučaju da se nehotice proguta, odmah potražiti pomoć liječnika i pokažite mu uputu o VMP ili etiketu.
In the case of accidental self injection, seek medical advice immediately and show the package insert or label to a physician.
U slučaju nehotičnog samoinjiciranja, odmah potražiti pomoć liječnika i pokazati mu uputu o VMP ili naljepnicu.
In the case of accidental self –injection, headache, bone and muscle pain may occur.
U slučaju da se nehotično samoinjicira, mogu se pojaviti glavobolja i bol u kostima i mišićima.
In the case of accidental self-injection, seek medical advice immediately and show the package insert or label to the physician.
U slučaju nehotičnog samoinjiciranja, hitno zatražiti savjet liječnika i pokazati mu uputu ili etiketu.
In the case of accidental self-injection, seek medical advice immediately and show the package leaflet or label to the physician.
U slučaju nehotičnog samoinjiciranja, hitno zatražiti pomoć liječnika i pokažite mu uputu o VMP ili etiketu.
In the case of adrenal insufficiency and depending on the severity of the event, the dose of Ketoconazole HRA should be decreased by at least 200 mg/day or the treatment should be temporarily discontinued and/or a corticosteroid therapy should be added until the resolution of the event.
U slučaju insuficijencije nadbubrežne žlijezde te ovisno o težini događaja, dozu Ketoconazolea HRA treba smanjiti za najmanje 200 mg/dan ili liječenje treba privremeno prekinuti i/ili treba dodatno uvesti kortikosteroidnu terapiju dok se događaj ne riješi.
In the case of adverse clinical signs, treat symptomatically.
U slučaju štetnih kliničkih znakova, životinju se mora liječiti simptomatski.
In the case of adverse reactions such as dizziness, which has been reported with leflunomide, the parent compound, the patient’s ability to concentrate and to react properly may be impaired.
U slučaju nuspojava poput omaglice, koja je primijećena kod primjene leflunomida, ishodišnog spoja, bolesniku može biti smanjena sposobnost koncentracije i ispravnog reagiranja.
In the case of adverse reactions, doses might be reduced to once daily doses of 9 mg/kg bodyweight (range 7.5–10.5 mg/kg) or 6 mg/kg bw (range 4.5–7.5 mg/kg) according to the tables below.
U slučaju nuspojava, doze se mogu smanjiti na jednodnevne doze od 9 mg/kg tjelesne težine (raspon 7.5 – 10.5 mg/kg) ili 6 mg/kg tjelesne težine (raspon 4.5 - 7.5mg/kg) prema tablicama u nastavku.
In the case of an increase in liver enzymes equal to or greater than 3 times the upper limit of normal, Ketoconazole HRA should be stopped immediately and should not be reintroduced due to the risk of serious hepatic toxicity.
Ako je povećanje jetrenih enzima jednako ili veće od trostruke gornje granice normalnih vrijednosti, terapiju Ketoconazoleom HRA treba odmah prekinuti te je se ne smije ponovno uvoditi zbog rizika od ozbiljne hepatičke toksičnosti.
In the case of an increase in liver enzymes of less than 3 times the upper limit of normal, more frequent monitoring of liver function tests should be performed and the daily dose should be decreased by at least 200 mg.
U slučaju povećanja razine jetrenih enzima za manje od trostruke gornje granice normalnih vrijednosti, treba češće kontrolirati funkciju jetre, a dnevnu dozu treba smanjiti za najmanje 200 mg.
In the case of an overdose hypotensive/vasovagal reaction might be anticipated as well as headache, flushing, nausea, vomiting, and diarrhoea.
U slučaju predoziranja može se očekivati hipotenzivna/vazovagalna reakcija, kao i glavobolja, crvenilo uz osjećaj vrućine, mučnina, povraćanje i proljev.
In the case of associated clinical symptoms of liver injury, i.e., nausea, vomiting, fever, abdominal pain, jaundice, unusual lethargy or fatigue, flu-like syndrome (arthralgia, myalgia, fever), treatment must be stopped and re-introduction of STAYVEER is not to be considered.
U slučaju drugih kliničkih simptoma oštećenja jetre, tj. mučnine, povraćanja, vrućice, bolova u abdomenu, žutice, neuobičajene slabosti ili umora, simptoma sličnih gripi (artralgija, mialgija, vrućica), liječenje treba prekinuti bez razmatranja ponovnog liječenja STAYVEEROM.
In the case of associated clinical symptoms of liver injury, i.e., nausea, vomiting, fever, abdominal pain, jaundice, unusual lethargy or fatigue, flu-like syndrome (arthralgia, myalgia, fever), treatment must be stopped and re-introduction of Tracleer is not to be considered.
U slučaju drugih kliničkih simptoma oštećenja jetre, tj. mučnine, povraćanja, vrućice, bolova u abdomenu, žutice, neuobičajene slabosti ili umora, simptoma sličnih gripi (artralgija, mialgija, vrućica), liječenje treba prekinuti bez razmatranja ponovnog liječenja Tracleerom.
In the case of bleeding, dose interruptions, adjustments, or discontinuation may be necessary (see section 4.2).
U slučaju krvarenja može biti potrebno privremeno prekinuti doziranje, prilagoditi dozu ili prestati s primjenom (vidjeti dio 4.2).
In the case of bleeding, please contact your doctor before stopping the intake of Pradaxa®.
U slučaju krvarenja, molimo, obratite se svom liječniku prije prekida uzimanja Pradaxe®.
In the case of clinical deterioration (e.g., decrease in 6-minute walk test distance by at least 10% compared with pre-treatment measurement) despite STAYVEER treatment for at least 8 weeks (target dose for at least 4 weeks), alternative therapies should be considered.
U slučaju kliničkog pogoršanja (npr. smanjenje prijeđene udaljenosti u 6-minutnom testu hoda za najmanje 10% u odnosu na mjerenje prije liječenja) unatoč liječenju STAYVEEROM u trajanju od najmanje 8 tjedana (ciljna doza uzimana najmanje 4 tjedna), potrebno je razmotriti alternativne terapije.
In the case of combination therapy with Pegasys and ribavirin, please follow the dosing regimen recommended by your doctor.
Ako Vam je propisano liječenje lijekom Pegasys u kombinaciji s ribavirinom, molimo pridržavajte se načina doziranja koji Vam je propisao liječnik.
In the case of combination therapy with Pegasys, please follow the dosing regimen recommended by your doctor and refer also to the package leaflets of any other medicines that are used in combination with Pegasys.
Ako Vam je propisano kombinirano liječenje lijekom Pegasys, molimo pridržavajte se načina doziranja koji Vam je propisao liječnik i također pogledajte i Upute o lijeku svih ostalih lijekova koje koristite u kombinaciji s lijekom Pegasys.
In the case of increase of liver enzymes levels above 3 times the upper limit of normal, Ketoconazole HRA should be stopped immediately and should not be reintroduced because of the risk of serious hepatic toxicity.
Ako je povećanje jetrenih enzima veće od trostruke gornje granice normalnih vrijednosti, terapiju Ketoconazoleom HRA treba odmah prekinuti te se ne smije ponovno uvoditi zbog rizika od ozbiljne hepatičke toksičnosti.
In the case of injections under the skin, the weekly dose can be given either as 1 injection per week or as 3 divided injections per week.
U slučaju injekcije potkožno, tjedna doza može se primijeniti bilo kao 1 injekcija tjedno ili u 3 podijeljene injekcije tjedno.
In the case of late clinical deterioration despite treatment with STAYVEER (i.e., after several months of treatment), the treatment should be re-assessed.
U slučaju naknadnog pogoršanja kliničke slike unatoč uzimanju STAYVEERA (tj. nakon nekoliko mjeseci liječenja), treba ponovo razmotriti način liječenja.
In the case of late clinical deterioration despite treatment with Tracleer (i.e., after several months of treatment), the treatment should be re-assessed.
U slučaju naknadnog pogoršanja kliničke slike unatoč uzimanju Tracleera (tj. nakon nekoliko mjeseci liječenja), treba ponovo razmotriti način liječenja.
In the case of low to medium levels of maternally derived antibodies against PCV2 a single vaccination (2 ml) to pigs from an age of 3 weeks onwards is advised.
U slučaju niske do srednje razine materalnih antitijela protiv PCV2 savjetuje se jedno cijepljenje (2 ml) svinja starih 3 tjedna.
In the case of low to medium levels of maternally derived antibodies against PCV2 a single vaccination (2 ml) to pigs from an age of 3 weeks onwards is advised.
U slučaju niske do srednje razine maternalnih“ antitijela protiv PCV2 savjetovano je jedno cijepljenje (2 ml) za svinje stare 3 tjedna.
In the case of major surgical interventions in particular, a precise monitoring of the substitution therapy by means of coagulation analysis (plasma FVIII activity) is indispensable.
Posebice u slučaju većih kirurških zahvata neophodno je precizno praćenje nadomjesne terapije analizom koagulacije (aktivnost plazmatskog FVIII).
In the case of major surgical interventions in particular, a precise monitoring of the substitution therapy by means of coagulation analysis (plasma FVIII activity) is indispensable.
Posebice u slučaju većih kirurških zahvata, neophodno je precizno praćenje nadomjesne terapije analizom koagulacije (aktivnost plazmatskog FVIII).
In the case of major surgical interventions in particular, a precise monitoring of the substitution therapy by means of coagulation analysis (plasma FVIII activity) is indispensable.
Posebice u slučaju većih kirurških zahvata, potrebno je precizno praćenje nadomjesne terapije analizom koagulacije (aktivnost plazmatskog FVIII).